St Louis, Missouri, United StatesFounded 20106+ employeesPrivate
$8.9M raised· last: convertible note (Jan 2022)· 5 rounds
Backed by(10 investors)
Kemin Industries · LeadCultivation Capital · LeadThe Yield Lab · LeadArsenal Capital Partners · Lead+6 more
Aptimmune Biologics specializes in developing revolutionary mucosal vaccines that provide unsurpassed efficacy against the viral diseases most costly to the swine industry. We focus on swine vaccines and the prevention of two major diseases – Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza.
